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Abstract:   
The aim of the present study is to explore the molecular mechanisms of epithelial-
to-mesenchymal transition and fibroblast differentiation during the pathogenesis of 
idiopathic pulmonary fibrosis. 
 
We identified 6 up-regulated and 3 down-regulated miRNAs in a human lung 
epithelial cell EMT model using miRNA microarray and real-time PCR. Overexpression 
of one of these up-regulated miRNAs, miR-424, increased the expression of α-smooth 
muscle actin, an indicator of myofibroblast differentiation, but had no effects on the 
epithelial or mesenchymal cell markers. miR-424 enhanced the activity of the TGF-β 
signaling pathway, as demonstrated by a luciferase reporter assay. Further experiments 
showed that miR-424 decreased the protein expression of Smurf2, a negative regulator of 
TGF-β signaling, indicating that miR-424 exerts a forward regulatory loop in the TGF-β 
signaling pathway. Our results suggest that miR-424 regulates the myofibroblast 
differentiation during EMT by potentiating the TGF-β signaling pathway, likely through 
Smurf2. 
 
Furthermore, we investigated the role of EZH2 in the differentiation of fibroblasts 
into myofibroblasts and underlying mechanisms. We found that EZH2 was up-regulated 
in the lungs of patients with IPF and mice with bleomycin-induced lung fibrosis. The up-
regulation of EZH2 occurred in myofibroblasts. The inhibition of EZH2 by its inhibitor 
DZNep or shRNA reduced TGFβ1-induced differentiation of human lung fibroblasts into 
myofibroblasts as demonstrated by the expression of myofibroblast marker α-smooth 
muscle actin, fibronectin and COL4A1 as well as contractility. DZNep inhibited Smad2/3 
nuclear translocation without affecting Smad2/3 phosphorylation. Co-
immunoprecipitation revealed a direct interaction between EZH2 and Smad2/3. DZNep 
treatment attenuated bleomycin-induced pulmonary fibrosis in mice. We conclude that 
EZH2 induces the differentiation of fibroblasts to myofibroblasts by binding and 
retaining Smad2/3 in the nucleus. 
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CHAPTER I 
 
 
INTRODUCTION 
1.1 Idiopathic pulmonary fibrosis 
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing 
interstitial pneumonia and is associated with the histopathologic and radiologic pattern of usual 
interstitial pneumonia (UIP) [1, 2]. IPF is one of the most common forms of interstitial lung 
disease (ILD) which requires the exclusion of ILD associated with environmental exposure, 
medication, or systemic disease [1, 3]. IPF is characterized by deterioration of respiratory 
functions due to fibrosis of the lung interstitium. The clinical features include chronic exertional 
dyspnea, dry cough, bibasilar inspiratory crackles, and digital clubbing [1]. The criteria for the 
diagnosis of IPF include: 1) exclusion of other known causes of ILD; 2) the presence of a UIP 
pattern on high-resolution computed tomography (HRCT) in patients not subjected to surgical 
lung biopsy; and 3) Specific combinations of HRCT and surgical lung biopsy patterns in patients 
subjected to surgical lung biopsy [1]. The features of UIP on HRCT are subpleural, basal 
predominance, reticular abnormality, and honeycombing [1]. Histopathological criteria for UIP 
are composed of fibroblastic foci, patchy of fibrosis, and architectural distortion with 
honeycombing [1]. In the USA, the prevalence of IPF is estimated to be 14 - 27.9 cases per 
100,000 population using narrow case definitions, and 42.7 - 63 per 100,000 population using 
broad case definitions. The annual incidence of IPF in the USA was estimated to be 6.8 - 8.8 per  
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100,000 population using narrow case definitions, and 16.3 - 17.4 per 100,000 population using broad 
case definitions [4].  
The progression of disease has been described as a progressive decline in pulmonary function 
until eventual death from respiratory failure or complicating comorbidity [1]. The progression for 
each individual patient is unpredictable at the time of diagnosis. The majority of patients experience a 
slowly progressive decline over several to many years. Some of them remain stable or have an 
accelerated decline while others may have episodes of acute exacerbation [1]. The median survival 
time from diagnosis is 2 - 3 years according to several retrospective studies, and the mortality during 
3-5 years after diagnosis is 50% [1, 5]. Worse prognosis has been associated with old age, smoking 
history, low body-mass index (BMI), digital clubbing, physiological impairment, UIP, and pulmonary 
hypertension [5, 6]. Most deaths (77%) in IPF are due to respiratory related causes including 
progression of IPF, acute exacerbation, acute lung injury, pneumonia and cor pulmonale. Other deaths 
(23%) are due to cardiac causes, sepsis, cancer, and other causes [5]. Potential risk factors are 
cigarette smoking [1, 7], ageing [8], environmental exposures to metal dusts (brass, lead, and steel) 
and wood dust (pine) [9, 10], chronic viral infection (Epstein-Barr virus and hepatitis C) [11-13], 
gastroesophageal reflux (GER) [14, 15], and diabetes mellitus [15].  
Patients with IPF were traditionally treated with corticosteroid and immunosuppressant 
therapy and N-acetyl-cysteine until two studies showed negative results [16, 17]. Recently, two new 
medications, pirfenidone and nintedanib, have been approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of IPF on October 2014. Pirfenidone inhibits fibroblast 
proliferation and collagen synthesis by regulating TGFβ and TNF-α whereas nintedanib inhibits the 
tyrosine kinase receptors for PDGF, VEGF and FGF. Both drugs have been shown to reduce the 
decline in forced vital capacity (FVC) [18]. 
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The exact etiology of IPF is still unclear. Several studies have suggested that genetic 
predisposition is involved in IPF. Mutations in SFTPC gene and deficiency of SP-C were linked to 
IPF [19-23]. Mutations in SFTPC cause disruption of surfactant synthesis, which further induce 
protein misfolding and endoplasmic reticulum (ER) stress that produce the unfolded protein response 
(UPR) in alveolar epithelial type II cells. UPR induces apoptosis of alveolar type II cells, which 
disrupts the integrity of the alveolar epithelium [24-26]. Similarly, mutations of SFTPA2 have been 
associated with pulmonary fibrosis and lead to protein instability and ER stress [27, 28].  
Telomerase mutations and telomere shortening are observed in patients with IPF. Mutations 
in the telomerase genes TERT and TERC have been found in both familial and sporadic cases [29-31]. 
Shorter telomeres have also been found in some IPF patients [32, 33]. Telomerase shortening may 
explain the increased occurrence of IPF in older individuals. Pulmonary fibrosis has been observed in 
a group of patients with dyskeratosis congenital, which have short telomeres due to DKC1 gene 
mutations [29, 30]. 
An increase in MUC5B gene common promoter polymorphism is associated with IPF [34, 
35]. However, MUC5B is overexpressed even without the genetic variants, indicating another 
independent regulation of this gene may be involved. 
Epigenetic regulation in IPF has also been studied. Abnormality in histone hypoacetylation in 
fibroblasts causes down-regulation of cyclooxygenase 2 (COX-2), which reduces the production of 
the antifibrotic protein prostaglandin E2 [36]. Histone deacetylation and hypermethylation are 
responsible for the repression of another antifibrotic gene gamma interferon (IFN-γ)-inducible protein 
of 10 kDa (IP-10) [37]. Other dysregulated genes due to abnormality in epigenetics include Thy-1, 
p14(ARF), and Fas [38-40]. Notably, methylation of 3 CpG islands in the promoter of the α-SMA 
gene has been shown to directly regulate the expression of α-SMA and fibroblast differentiation [41]. 
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DNA methylation profiling studies have also shown a changed methylation pattern of CpG islands 
[42, 43].   
The original hypothesis for the pathogenesis of IPF is that chronic inflammation causes 
alveolar epithelial cell injury, which leads to progressive fibrosis. There are several weaknesses with 
this theory. Inflammation is not a prominent histological finding, epithelial injury may stimulate 
fibrosis without inflammation, and anti-inflammatory therapy does not improve outcome of IPF [17, 
44]. The new accepted hypothesis is that repetitive epithelial microinjuries result in abnormal 
activation of epithelial cells and aberrant wound healing, leading to the formation of the 
fibroblast/myofibroblast foci. These foci are frequently observed in IPF biopsy and correlated to 
survival [45, 46]. In the foci, myofibroblasts secrete excessive amounts of extracellular matrix (ECM) 
proteins, mainly fibrillar collagens. In this progressive abnormal lung remodeling, several 
neighboring scars, together with the disproportionate secretion of some enzymes can provoke the 
formation of the honeycomb cysts through mechanical forces [6]. 
1.2 Epithelia-to-mesenchymal transition and pulmonary fibrosis 
Most tissues and organs development involves several conversions of epithelial cells to 
mesenchymal cells through the process of epithelial-to-mesenchymal transition (EMT) and the 
reversed mesenchymal-to-epithelial transition (MET) [47]. EMT is a process whereby epithelial cells 
undergo transition to a mesenchymal phenotype. During EMT, epithelial cells lose phenotypic 
features, such as apical-basal polarity and specialized cell-cell adhesions, and acquire mesenchymal 
cell properties such as increased cell mobility and invasive property [47, 48]. EMT is essential for the 
early stages of development of most tissues. During development, several rounds of EMT and MET 
are required. These sequential rounds are referred to as primary, secondary, and tertiary EMT [47]. 
Primary EMT enables the development of the mesoderm from the epithelium during gastrulation, 
which is necessary for the formation of organs such as the lung and heart. It also participates in the 
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delamination of neural crest cells from the dorsal neural tube [47]. Later on, early mesodermal cells 
will condense into transient epithelial structures, which undergo secondary EMT to generate 
mesenchymal cells that differentiate into specific cells [47]. The endothelial cells from the 
atrioventricular canal to form the endocardial cushion is an example of tertiary EMT [47, 49]. EMT is 
also required during wound healing as a physiological response [50, 51].  
While EMT is an integral process during development, it also contributes to the progression 
of tumors and to fibrosis in fully developed organs. In cancer, tumor cells become more invasive after 
undergoing EMT, which facilitates the metastasis and progression of the tumor [52]. Studies have 
found that loss of epithelial markers such as E-cadherin, and expression of mesenchymal proteins 
such as vimentin correlates with poor prognosis [53]. The release of single cell through EMT is found 
during the invasion of adenocarcinoma [53]. Several studies have demonstrated that change of 
epithelial marker E-cadherin expression changes tumor invasive behavior [53, 54]. On the other hand, 
overexpression of twist, a TGF- β signaling pathway transcription factor, promotes EMT as well as 
the metastatic potential of tumor cells [55].  
EMT not only occurs as a physiological response to injury, but it also occurs after tissue 
injury and/or stress and induces organ degeneration such as fibrosis. Many studies provide convincing 
evidence to support the hypothesis that a significant portion of the myofibroblasts in tissue fibrosis 
come from epithelial cells which have undergone EMT [47, 48, 53, 56-59]. Now we know cells of 
renal tubules, lens epitheliaum, hepatocytes all can undergo EMT [47]. Indeed, one study compared 
alveolar type II cells from fibrotic and normal human lungs. They found that cells from the lungs of 
patient with IPF had a higher expression of mesenchymal markers such as type I collagen. They also 
found that alveolar type II cells could acquire features of mesenchymal cells [60]. In vitro and in vivo 
studies suggest that alveolar epithelial cells can acquire mesenchymal characteristics in response to 
injury [56, 60-63].  
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Many signaling pathways are known to regulate EMT, including the TGF-β, Wnt and Notch 
pathways. These pathways do not operate independently; rather, crosstalk between them ensures 
EMT completion. The signaling pathway that conveys TGF-β inputs (TGFβ1) from membrane 
receptors to target genes is well studied, and is considered the central player in EMT. In lungs, 
TGFβ1 is synthesized and secreted, mainly by macrophages and epithelial cells, as a latent cytokine 
bound to latency-associated peptide (LAP) that both sequesters the cytokine's activity and localizes 
the cytokine to ECMs [64]. Activation of TGFβ1 in epithelial cells requires binding of latent TGFβ1 
to integrin αvβ6 on epithelial cells, and then the activation of the integrin by G protein-coupled 
responses to proinflammatory agonists, such as thrombin or LPA2, further activate TGFβ1  [65-67]. 
Activation of TGF-β signaling pathway also requires loss of normal cell contacts, which triggers the 
assembly of signaling complexes that contain E-cadherin/β-catenin, integrin α3β1, and TGFβ1 
receptors. The induced transcriptional complexes, tyrosine-phosphorylated β-catenin and 
phosphorylated Smads (p-Smads), move and accumulate in the nucleus to reprogram epithelial cells 
towards EMT [68].  
1.3 Fibroblast differentiation and pulmonary fibrosis 
Several possible origins for the IPF fibroblasts/myofibroblasts foci have been proposed, 
including resident fibroblasts, epithelial cells (via EMT), and bone marrow-derived cells (fibrocytes) 
[6]. Activated alveolar epithelial cells (AECs)  secrete various mediators such as platelet-derived 
growth factor (PDGF), tumor necrosis factor α, TGFβ, and endothelin 1, which cause migration, 
proliferation and differentiation of resident fibroblasts [69]; AECs also have a high expression of 
chemokine CXCL12 and circulating fibrocytes express the chemokine receptor CXCR4, suggesting 
that fibrocytes are recruited through CXCR4-CXCL12 axis [70]; AECs may directly contribute to the 
fibroblasts/myofibroblasts population through the EMT [60, 62, 71].  
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Activated fibroblasts can differentiate into contractile and secretory myofibroblasts which 
cause excessive contraction and extracellular matrix (ECM) deposition. The hallmark of 
differentiated myofibroblasts is the expression of α-smooth muscle actin (α-SMA). At least three 
actors are required to induce fibroblast differentiation: local accumulation of active TGFβ1, high 
extracellular mechanical stress, and the presence of specialized ECM proteins [72]. Differentiated 
myofibroblasts exaggerate the ECM accumulation. They secrete angiotensinogen and hydrogen 
peroxide, which induce AEC apoptosis. They also produce matrix metalloproteinases, which disrupt 
the basement membrane [73, 74]. Fibroblasts and myofibroblasts in IPF are more resistant to 
apoptosis, causing persistent foci in the lung tissue [75].  
1.4 TGF-β signaling pathway 
The signaling pathway that conveys TGF-β inputs from membrane receptors to target genes 
is well studied. TGF-β binds trans-membrane serine–threonine kinase receptors on the cell surface, 
leading to the formation of a bi-dimeric receptor complex of receptor type I (TβRI) and type II 
(TβRII). TβRII phosphorylates and activates TβRI, which then phosphorylates cytoplasmic Smad2/3 
transcription factors, allowing them to translocate into the nucleus. Smad4 acts as a partner with 
Smad2/3 to facilitate this process. In contrast, Smad6 and Smad7 inhibit the activated receptor-
regulated Smad2/3. Three families of the transcription factors (Snail, ZEB and bHLH) are all 
involved in the TGF-β transcription program. Their expression is regulated either directly through a 
Smad-dependent pathway, or indirectly through other transcription factors. These transcription factors 
repress epithelial genes (e.g., E-cadherin and zonula occludens-1) and activate mesenchymal genes 
(e.g., N-cadherin and α-smooth muscle actin) [76]. Nuclear import of Smad3 requires a nuclear 
localization sequence (NLS) in the MH1 domain, which is exposed by phosphorylation, allowing its 
binding importin-β. Smad2 importing is independent of importin-β but requires MH2 domain. In the 
nucleus, phosphor-Smad2/3 are dephosphorylated by PPM1A and exported to the cytoplasm, which 
requires the interaction between MH2 domain and nucleoporins CAN/Nup214 and Nup153 [77]. 
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Functionally, the TGF-β signaling pathway plays a predominant role in tissue fibrosis by 
influencing processes such as EMT, fibroblast recruitment, fibroblast contractility, myofibroblast 
differentiation, and ECM deposition [78-81]. 
 
Fig. I.1. Structural organization and role of the domains of Smads [77].  
1.5 microRNA in pulmonary fibrosis 
MicroRNAs (miRNAs) are a group of small non-coding RNAs that are 18-24 nt in length and 
regulate gene expression at the post-transcriptional level. miRNAs are first transcribed from miRNA 
genes by RNA polymerase II, then cleaved by Drosha/Dicer to become mature miRNAs. The mature 
single-stranded miRNA is incorporated into the RNA-induced silencing complex (RISC), which 
binds to target mRNAs to inhibit protein translation or to cleave the mRNAs. miRNAs regulate both 
physiological and pathological processes [82-86].  
A number of miRNAs have been reported to be involved in fibrotic diseases [86]. The miR-
200 family and miR-205 target ZEB1 and SIP1, two important transcriptional factors in the TGF-β 
pathway, and inhibit EMT in renal epithelial cells [87, 88]. Recently, miR-424 has been shown to 
induce EMT in cancer cells [89]. Several other miRNAs are also implicated in fibrotic lung diseases. 
TGF-β1 induces miR-21 expression, and miR-21 in turn promotes activation of fibroblasts by 
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inhibiting Smad7 [90]. miR-155 targets the keratinocyte growth factor in lung fibroblasts to induce 
fibrosis [91]. Knock-down of miR-29 increases several pro-fibrotic genes in lung fetal fibroblasts [92]. 
A decrease in Let-7d is observed in the lungs of IPF patients, and studies in rat lung epithelial cells 
suggest that Let-7d contributes to EMT through its target, HMGA2 [88]. However, no direct evidence 
has been presented to show that miRNAs regulate EMT in human lung epithelial cells.  
1.6 Enhancer of zeste homolog 2 (EZH2) 
Enhancer of zeste homolog 2 (EZH2) is the catalytic component of a multiprotein complex, 
Polycomb Repressive Complexes 2 (PRC2) [183]. PRC2 catalyzes trimethylation of histone H3 
lysine 27 (H3K27me3). EZH2 contains a SET domain which provides the methyltransferase active 
site, although EZH2 alone exhibits no intrinsic enzymatic activity. In order to attain catalytic activity 
it must be complexed with at least two proteins, embryonic ectoderm development (EED) and 
suppressor of zeste 12 (SUZ12) [93-95]. These three proteins combine with the histone binding 
proteins retinoblastoma binding protein 4 (RBBP4) and RBBP7 to form the core component of PRC2 
[96]. Besides interacting with PRC2 components, EZH2 also interacts with other proteins including 
the transcription factor YinYang1 (YY1) [97, 98] and nuclear inhibitor of protein Ser/Thr phosphate-
1 (NPP1) [99]. Over-expression of EZH2 has been associated with several cancers including prostate 
cancer, breast cancer, bladder cancer and lung cancer [100, 101]. Cigarette smoke induces EZH2 
mediated repression of the Wnt signaling inhibitor Dickkopf-1 in lung cancer cells [102]. EZH2 is 
also the target of miR-101 and the genomic loss of miR-101 in cancer leads to over-expression of 
EZH2, resulting in cancer progression [103, 104].  
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Fig.I.2. Architecture of PRC2 and its components [183]. (A) Models of PRC2. (B) Domain structure of components of 
PRC2. Domain “1”, binding region for PHF; domain “2”, binding region for SUZ12; CXC, cysteine-rich domain; SANT, 
domain that allows chromatin remodeling protein to interact with histones; SET, catalytic domain of EZH2; 
1.7 Specific aims and significances 
In spite of the great progress on the study of the pathogenesis of IPF, the exact cause is still 
unknown. IPF is still a disease with poor prognosis. EMT and fibroblast differentiation have been 
considered as two of the main players in this process, though there are still a lot of questions need to 
be answered. Thus, the present study is designed to better understand the molecular mechanism 
behind EMT, fibroblast differentiation of IPF. We have laid down two specific objectives: 
Specific Aim I: Investigate the regulation of myofibroblast differentiation by miR-424 during 
epithelial-to-mesenchymal transition 
Specific Aim II: Explore the role of EZH2 on myofibroblast differentiation in idiopathic pulmonary 
fibrosis 
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CHAPTER II 
 
 
MATERIALS AND METHODS 
 
2.1 Culture of human LL29 cells 
Human lung fibroblasts (LL29, AnHa), isolated from a 26 years old female Caucasian, 
were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and cultured 
in F-12K medium (Kaighn's Modification of Ham's F-12 Medium, ATCC), supplemented with 1% 
penicillin/streptomycin and 10% heat-inactivated fetal bovine serum (FBS). Cells were grown in 
cell culture flasks in a cell culture incubator at 37oC in a humidified atmosphere containing 5% 
carbon dioxide. Culture medium was changed every 3 days.  
2.2 Cell model of fibroblast activation and inhibition 
LL29 cells were sub-cultured after reaching 100% confluence. The cells were trypsinized 
using 0.05% Trypsin-EDTA (Thermo Fisher Scientific, Grand Island, NY) and counted under a 
microscope. 1.6×105 cells per well were cultured in full F12-K culture medium in 12-well plates. 
After reaching 70% confluence, the cells were treated with 4 µM of 3-Deazaneplanocin A 
hydrochloride (DZNep, Sigma-Aldrich, St. Louis, MO) for 24 hours, followed by stimulation 
with 5 ng/ml of recombinant human TGF-β1 (R&D Systems, Minneapolis, MN) for another 24 
hours. The cells were then washed with ice-cold phosphate-buffered saline (PBS, Thermo Fisher 
Scientific, Grand Island, NY) and collected either with Tri Reagent (Molecular Research Center, 
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Cincinnati, OH) for RNA isolation or M-PER Mammalian protein extraction reagent (Thermo 
Fisher Scientific, Grand Island, NY) plus Halt protease and phosphatase inhibitor cocktail 
(Thermo Fisher Scientific) for protein extraction. These samples were stored in – 80°C until use.  
2.3 Culture of human A549 cells 
Human lung epithelial cells (A549) were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA) and cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM), supplemented with 1% penicillin/streptomycin and 10% heat-inactivated fetal bovine 
serum (FBS). Cells were grown at 37oC in a humidified atmosphere containing 5% CO2.	Cell 
model of EMT 
A549 cells (1.6 x 105 per well) were cultured in DMEM, supplemented with 10% 
charcoal-stripped FBS in 6-well plates. After reaching 60% confluence, the cells were treated 
with 5 ng/ml of recombinant human TGF-β1 (R&D Systems, Minneapolis, MN) or with vehicle 
alone for 4, 8 and 12 days. The concentration of TGF-β1 used in our study (5 ng/ml) was based 
on the report from literature [107] and was physiologically relevant [108]. To avoid confluence, 
the cells were split every 4 days using trypsin. One third of the cells were reseeded in the original 
plates, while the other two thirds were collected for mRNA and protein analyses.  
2.4 Human lung tissue 
Twenty-eight lung tissue samples from IPF patients were obtained from Lung Tissue 
Research Consortium (LTRC). The tissues were divided into three groups according to the 
predicted probronchodialator forced vital capacity (FVC) of the patients: > 80% (n = 8), 50% - 80% 
(n = 10), and < 50% (n = 10). The lung tissues were stored in RNAlater solution -80°C until use. 
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2.5 Real-time PCR 
Total RNA was isolated from cultured A549 LL29 cells, human or animal lung tissues 
using TRI Reagent following the manufacturer’s instructions. Briefly, the samples in Tri Reagent 
were homogenized and waited for 5 minutes at room temperature to allow the complete 
dissociation of nucleoprotein complexes. Then, 0.1 ml 1-bromo-3-chloropropane (BCP) was 
added to 1 ml of the homogenate. The samples were mixed vigorously for 15 seconds, incubated 
at room temperature for 10 minutes, and centrifuge at 12,000 g for 15 minutes at 4°C. The upper 
aqueous phase was transferred to a new tube and mixed with 0.5 ml of isopropanol. The mixture 
was incubated at room temperature for 10 minutes and centrifuge at 12,000 g for 8 minutes at 4°C. 
The supernatant was removed. The white RNA pellet was washed with 75% ethanol, and 
centrifuged at 7,500 g for 5 minutes at 4°C. The RNA pellet was air-dried for 5 minutes and 
dissolved in RNase- and DNase-free distilled water. The RNA concentration and quality was 
determined using NanoDrop ND-1000 Spectrophotometer (NanoDrop Tech., Rockland, DE). The 
A260/A280 and A260/A230 of the RNA samples were greater than 1.8 and 1.7, respectively. 
Two µg of RNA was treated with TURBO DNase (Ambion, Austin, TX) in a 50 µl reaction 
buffer to remove genomic DNA contamination. The DNase was inactivated by performing a 
phenol/chloroform extraction. One µg of RNA was reverse-transcribed into cDNA using M-MLV 
reverse transcriptase, random primers, and oligo dT (all from Promega, Madison, WI). cDNA was 
diluted to 1:100 for real-time PCR of all mRNAs and 1:1,000 for 18S rRNA housekeeping gene. 
Real-time PCR was carried out on a 7900HT Fast Real-Time PCR System (Applied Biosystems, 
Foster City, CA) using 7500 software V2.3. The primers were designed using Primer Express 
software (Applied Biosystems) . Primers for miR-424 study are listed in Table II.1, and primers 
for EZH2 study are listed in Table II.2. The reaction system was 20 µl consisted of one µl each of 
10 mM of forward and reward primers, 3 µl of water, 10 µl of qPCR Mastermix Plus for SYBR 
Green I – Low ROX (AnaSpec, Fremont, CA), and 5 µl of diluted cDNA. The thermal condition 
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was 95°C for 10 min, followed by 40 cycles of 95°C 15 s, and 60°C for 60 s. The mRNA levels 
of each gene were calculated using comparative CT (∆∆CT) method. ∆CT was first calculated as 
mRNA CT minus housekeeping gene CT and then converted to the linear form of relative 
expression by the 2^(-∆CT) calculation. 
Real-time PCR for miRNAs was carried out as previously described [109, 110]. Briefly, 
two µg of total RNA, without DNase treatment, was polyadenylated using a Poly(A) polymerase 
tailing kit  (Epicentre, Madison, WI). One µg of the poly(A) tailed RNA was then reverse-
transcribed into cDNA using M-MLV reverse transcriptase, oligo dT and miRNA RT primers, 
including a universal reverse primer and a specific forward primer for each target miRNA listed 
in Table 2. Real-time PCR was performed using miRNA PCR primers (Table II.3). Data were 
normalized to RNU6B small RNA.  
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Table II.1: Real-time PCR primers for human mRNAs in miR-424 study 
 
CDH1 Forward 5’ TGCCCAGAAAATGAAAAAGG 
CDH1 Reward 5’ GTGTATGTGGCAATGCGTTC 
CDH2 Forward 5’ CTGCACAGATGTGGACAGGATT 
CDH2 Reward 5’ TTCTTTATCCCGGCGTTTCAT 
α-SMA Forward 5’ GAGAAGAGTTACGAGTTGCCTGA 
α-SMA Reward 5’ TGTTAGCATAGAGGTCCTTCCTG 
ZEB1 Forward 5’ AGCAGTGAAAGAGAAGGGAATGC 
ZEB1 Reward 5’ GGTCCTCTTCAGGTGCCTCAG 
SIP1 Forward 5’ CCACCACCTACAAGCTCACTCC 
SIP1 Reward 5’ AATGGCGATGGCGAGGAGAC 
E2A Forward 5’ TGTGCCAACTGCACCTCAA 
E2A Reward 5’ CCGTTTCAAACAGGCTGCTT 
Id2 Forward 5’ CGTGAGGTCCGTTAGGAAAA 
Id2 Reward 5’ AGGCTGACAATAGTGGGATG 
Id3 Forward 5’ ACTCACTCCCCAGCATGAAG 
Id3 Reward 5’ AAGCTCCTTTTGTCGTTGGA 
Snail1 Forward 5’ AGGATCTCCAGGCTCGAAAG 
Snall1 Reward 5’ GTAGCAGCCAGGGCCTAGAG 
Snail2 Forward 5’ CTGCGGCAAGGCGTTTTCCAGA 
Snail2 Reward 5’ CAGATGAGCCCTCAGATTTGAC 
Twist Forward 5’ CGGACAAGCTGAGCAAGATT 
Twist Reward 5’ CCTTCTCTGGAAACAATGAC 
CTGF Forward 5’ CAGCATGGACGTTCGTCTG 
CTGF Reward 5’ AACCACGGTTTGGTCCTTGG 
FN Forward 5’ AGCCTCGAAGAGCAAGAGG 
FN Reward 5’ CAAAACTTCAGCCCCAACTT 
Smurf1 Forward 5’ AGATCCGTCTGACAGTGTTATGT 
Smurf1 Reward 5’ AGATCCGTCTGACAGTGTTATGT 
Smurf2 Forward 5’ GGCAATGCCATTCTACAGATACT 
Smurf2 Reward 5’ CCACTTTGGATCAAGCGTATTCT 
Smad7 Forward 5’ ATAGCTAGCGCTTTACCGTGCAGATCAGCTT 
Smad7 Reward 5’ ATAGTCGACTTAATGGAACATAAACTCCTTT 
18S rRNA Forward 5’ CGTTGATTAAGTCCCTGCCCTT 
18S rRNA Reward 5’ TCAAGTTCGACCGTCTTCTCAG 
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Table II.2. Real-time PCR primers in EZH2 study 
 
Human-EZH2-FW TCCTACATCCTTTTCATGCAACAC 
Human-EZH2-RE CCCTCCAAATGCTGGTAACAC 
Mouse-EZH2-FW TGTGACCCTGACCTCTGTCTCA 
Mouse-EZH2-RE AGACGGTGCCAGCAGTAAGTG 
Human-18S-FW CGTTGATTAAGTCCCTGCCCTT 
Human-18S-RE TCAAGTTCGACCGTCTTCTCAG 
Mouse-18S-FW ATTGCTCAATCTCGGGTGGCTG 
Mouse-18S-RE CGTTCTTAGTTGGTGGAGCGATTTG 
Human-GAPDH-FW GAAGGTGAAGGTCGGAGTCAAC 
Human-GAPDH-RE CATGGGTGGAATCATATTGGAA 
Human-ACTB-FW GGCACCACACCTTCTACAATGA 
Human-ACTB-RE ACAGCCTGGATAGCAACGTACA 
Mouse-GAPDH-FW CTCGTCCCGTAGACAAAATGGT 
Mouse-GAPDH-RE TGATGGCAACAATCTCCACTTT 
Mouse-ACTB-FW GGCCAACCGTGAAAAGATGA 
Mouse-ACTB-RE TCCATCACAATGCCTGTGGTA 
Human-αSMA-FW GTGTTGCCCCTGAAGAGCAT 
Human-αSMA-RE CGCCTGGATAGCCACATACAT 
Mouse-αSMA-FW ATCCGATAGAACACGGCATCA 
Mouse-αSMA-RE CAGCAGTGTCGGATGCTCTTC 
Human-Fibronectin-FW CCTGCATCTGAGTACACCGTATC 
Human-Fibronectin-RE GGTCTCAGTCACCTCGGTGTT 
Human-COL4A1-FW CTCTGGCTGTGGCAAATGTG 
Human-COL4A1-RE CCTCAGGTCCTTGCATTCCA 
Mouse-COL1A1-FW ACGCATGGCCAAGAAGACAT 
Mouse-COL1A1-RE TTGTGGCAGATACAGATCAAGCA 
Mouse-COL3A1-FW CACCCTTCTTCATCCCACTCTT 
Mouse-COL3A1-RE TGACATGGTTCTGGCTTCCA 
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Table II.3: Primers for miRNA Reverse transcription and real-time PCR 
 
Reverse transcription Primers 
	
has-miR-Universe GTCGTGTCCAGTCGTGTGTT 
hsa-miR-1183 GCGAGCACAGAATTAATACGACTCACTATAGG(T)12GCCCA 
hsa-miR-23b-5p GCGAGCACAGAATTAATACGACTCACTATAGG(T)12AAATCA 
hsa-miR-1224-3p GCGAGCACAGAATTAATACGACTCACTATAGG(T)12CTGAGG 
hsa-miR-155 
GCGAGCACAGAATTAATACGACTCACTA
TAGG(T)12ACCCCT 
hsa-miR-298 GCGAGCACAGAATTAATACGACTCACTATAGG(T)12GGGAG 
hsa-miR-933 GCGAGCACAGAATTAATACGACTCACTATAGG(T)12GGGAGA 
hsa-miR-31 GCGAGCACAGAATTAATACGACTCACTATAGG(T)12AGCTAT 
hsa-miR-424 GCGAGCACAGAATTAATACGACTCACTATAGG(T)12CAAA 
hsa-miR-216b GCGAGCACAGAATTAATACGACTCACTATAGG(T)12CACAT 
hsa-miR-219-2-3p GCGAGCACAGAATTAATACGACTCACTATAGG(T)12ACAGCT 
hsa-miR-190 GCGAGCACAGAATTAATACGACTCACTATAGG(T)12ACCTAA 
hsa-miR-1273 GCGAGCACAGAATTAATACGACTCACTATAGG(T)12AAGAAA 
hsa-miR-582-5p GCGAGCACAGAATTAATACGACTCACTATAGG(T)12AGTAAC 
hsa-miR-487a GCGAGCACAGAATTAATACGACTCACTATAGG(T)12AACTGG 
hsa-miR-136-3p GCGAGCACAGAATTAATACGACTCACTATAGG(T)12AGACTC 
Real-time PCR  primers 
	
hsa-miR-1183 ACTGACCACTGTAGGTGATGGT 
hsa-miR-23b-5p CAATTATGGGTTCCTGGCATGC 
hsa-miR-1224-3p ATTAATCCCCACCTCCTCTCTC 
hsa-miR-155 GCCGGCTTAATGCTAATCGTGA 
hsa-miR-298 TACATAGCAGAAGCAGGGAGG 
hsa-miR-933 ATTATATGTGCGCAGGGAGACC 
hsa-miR-31 AGTCGTAGGCAAGATGCTGGC 
hsa-miR-424 GCTCGACAGCAGCAATTCATGT 
hsa-miR-216b CGAGCTAAATCTCTGCAGGCAA 
hsa-miR-219-2-3p CTGCATAGAATTGTGGCTGGAC 
hsa-miR-190 CCGCGCTGATATGTTTGATATA 
hsa-miR-1273 TCTAGTGGGCGACAAAGCAAGA 
hsa-miR-582-5p CGACGGTTACAGTTGTTCAACC 
hsa-miR-487a CGTGCGAATCATACAGGGACAT 
hsa-miR-136-3p GCTCGGCATCATCGTCTCAAAT 
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2.6 miRNA over-expression  
These studies utilized lentiviral miRNA expression vectors containing three elements, 
CMV-driven EGFP, followed by the mature miRNA sequence plus flanking sequences, which 
were then followed by the SV40 PolyA terminal sequence. The mature miRNA sequence and its 
5’ and 3’ flanking sequences of approximately 250 nt were PCR-amplified from human genomic 
DNA and cloned into the pLVX (Lenti-X) vector (Clontech, Mountain View, CA). The lentivirus 
was generated in HEK 293T cells using Lenti-X HTX packaging mix (Clontech). To determine 
the titer of viruses, different dilutions of viral stocks were used to infect 293T cells, followed by 
counting GFP-positive infected cells. A549 cells were infected with miRNAs or control lentivirus 
at MOI=50 for 24 h. After infection, virus-containing medium was removed and the cells were 
cultured for an additional 24 h in fresh medium.  
2.7 TGF-β reporter luciferase assay 
Four million HEK 293T cells were seeded on a 96-well plate. Fifty ng of a TGF-β 
reporter plasmid (SABiosciences, Valencia, CA), which contained a Smad transcriptional 
response element and a firefly luciferase reporter gene, and 100 ng of miR-424 lentiviral 
expression plasmid were co-transfected into HEK 293T cells using Lipofectamine 1000.  A 
lentiviral plasmid containing a scrambled sequence was used as a control. After 24 h of 
incubation, the cells were treated with TGF-β1 (5 ng/ml) or vehicle for 24 h and assayed using 
the Dual-Luciferase Reporter Assay System (Promega, Madison, WI).  
2.8 3’-UTR pmirGLO vector construction 
3’-UTR segments of three predicted targets, Smad7, Smurf1 and Smurf2 of miR-424, 
containing restriction sites NheI and SalI on the 5’ and 3’ ends, were amplified using PCR. Three 
PCR products and the pmirGLO empty vector (Promega, Madison, WI) were double-digested 
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using NheI and SalI restriction endonucleases (New England Biolabs, Ipswich, MA). The 3’-UTR 
segments were then inserted into the pmirGLO vector using T4 DNA ligase (New England 
Biolabs, Ipswich, MA). The inserts were confirmed by sequencing. 
2.9 Western blotting 
The cells were directly lysed in M-PER mammalian protein extraction lysis buffer 
(PIERCE, Rockford, IL) for 30 minutes on a rocker at 4°C whereas the tissue samples were 
homogenized in the lysis buffer. The lysate was centrifuged at 12,000 rpm for 15 minutes at 4°C. 
The supernatant was transferred to a tube and stored at -80°C. Protein concentration was 
determined using DC protein assay (Bio-Rad, Hercules, CA). Ten to twenty µg of proteins were 
mixed with 6X SDS protein loading buffer and water to a total volume of ten to twenty-five ml. 
Samples were separated on SDS–PAGE gel using Mini Trans-Blot system (Bio-Rad, Hercules, 
CA) at a constant voltage of 300 mV, and then were transferred to a nitrocellulose membrane 
using Semi-wet Trans-Blot turbo transfer system at a constant currant of 1.5 mA. The membranes 
were blocked with 10% non-fat milk for 60 minutes at room temperature, and then incubated 
overnight at 4°C with primary antibodies (See Table 2 for sources and dilutions). The membrane 
was washed using Tris-Buffered Saline with Tween 20 (TTBS) and incubated with goat anti-
mouse or goat anti-rabbit secondary antibodies (1:10000, Jackson ImmunoResearch, West Grove, 
PA) for 1 hour. The blots were then developed with enhanced chemiluminescence (ECL) reagents 
(PIERCE, Rockford, IL). Amersham Imager 600 (GE Healthcare Bio-Sciences, Pittsburgh, PA) 
was used to capture the images.  
2.10 Gel contraction assay  
The cells were trypsinized using trypsin EDTA and counted. Then the cells were mixed 
with collagen type 1 solution (BD Biosciences, San Jose, CA) with a final concentration of 1 
x105 cells/ml and 1 mg/ml of collagen. Fifteen µl of 0.5 N NaOH per 1 ml of the mixture were 
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added. An aliquot of five hundred µl of the mixture was distributed to each well of 12-well plates 
immediately and the plates were incubated in cell culture incubator for 30 minutes for 
polymerization. The polymerized gel was detached from the well wall and bottom using a 200 µl 
pipette tip and 500 µl of full growth medium with or without DZNep or TGFβ1 was added to 
each well. The plates were then returned to the incubator with 5% CO2 and 95% air. Photos of 
each well were taken after 48 hours. By using Image J software, surface areas of gel and well 
bottom were measured. Gel contraction activity was expressed as the ratio of gel to well bottom 
surface area.  
 
2.11 Nuclear and cytoplasmic extraction 
Nuclear and cytoplasmic fractions were separated using NE-PER nuclear and 
cytoplasmic extraction reagents (Thermo Fisher, Grand Island, NY). LL29 cells were harvested 
using trypsin-EDTA and then centrifuged at 500 xg for 5 minutes. Cell pellet was washed with 
PBS and centrifuged at 500 x g for 3 minutes. The supernatant was removed, leaving the cell 
pellet as dry as possible. One hundred µl of CER I reagent with proteinase inhibitor was added to 
the tube. Cells were fully suspended by vigorously vortexing and incubated on ice for 10 minutes. 
CER II (5.5 µl) was then added. Tubes were vortexed for 5 seconds and centrifuged at 20,000 xg 
for 5 minutes. The supernatant (cytoplasmic extract) was transferred to a new tube and stored at -
80°C. The remaining pellet was suspended in 50 µl of NER reagent with proteinase inhibitor. The 
tubes were vortexed vigorously for 15 minutes and placed on ice and continued vortexed for 15 
seconds every 10 minutes, for a total of 40 minutes. The tubes were then centrifuged at 20,000 x 
g for 10 minutes, and the supernatant (nuclear extract) was transferred to a new tube and stored at 
-80°C for western blotting analysis. 
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2.12 Immunohistochemistry 
Lung tissue sections were deparaffinized in xylene twice for 1 minute, and were hydrated 
in 100%, 95% and 70% alcohol and deionized water successively. Endogenous peroxidase 
activity was quenched using 0.3% H2O2 in water for 30 minutes at room temperature. The slides 
were blocked with 1.5% goat serum in PBS for 20 minutes at room temperature. The slides were 
then incubated for 60 minutes at room temperature with rabbit anti-EZH2 monoclonal antibodies 
(1:200 dilution, Cell Signaling Technology, Danvers, MA) in 1.5% goat serum in PBS. After 
being washed with PBS for 5 minutes, the slides were incubated with goat anti-rabbit biotinylated 
secondary antibodies (1:200 dilution) at room temperature for 30 minutes. Then the slides were 
incubated with ABC staining reagent (VECTASTAIN, Burlingame, CA) for 30 minutes. After 
the slides were washed in PBS for 5 minutes, they were incubated in peroxidase substrate to 
develop a desired color.  
For EZH2 and α-SMA double-staining, the procedure for EZH2 ABC staining was the 
same as described above. Following anti-EZH2 antibodies incubation, tissue sections were 
incubated with anti-α-SMA antibodies (1:200 dilution) overnight at 4°C together with anti-EZH2 
antibodies. ABC staining was performed for detecting EZH2, followed by incubation with Alexa 
Fluor 488 rabbit IgG fluorescent secondary antibody (1:3000, Life technologies, Grand Island, 
NY) for detecting α-SMA. Images were taken for bright field and fluorescence in the same field. 
2.13 Primary Mouse Fibroblasts/Myofibroblasts Isolation 
Fibroblasts and myofibroblasts were isolated from ten-week old of female C57BL/6 mice 
with or without bleomycin challenge according to the previous studies [113, 114]. The lungs were 
first trimmed to remove major airways and rinsed with PBS. Lung tissue then was transferred into 
100 mm cell culture dishes and minced into 1 to 2-mm3 pieces. Minced lung was incubated with 
5 ml of 0.25% Trypsin-EDTA (Thermo Fisher Scientific, Grand Island, NY) in cell culture 
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incubator at 37°C. At each of three 10-minute intervals, dishes were gently shaken by hand. After 
30 minutes, the cells were centrifuged at 1,200 rpm at 4°C for 10 minutes. The pellet was 
suspended in 10 ml of Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum, and transferred into 100 mm dishes. After 1 week of culture in the incubator 
at 37°C, nonadherent cells were removed while adherent cells were trypsinized and passed 
through 70 µm sterile cell strainers (Thermo Fisher Scientific, Grand Island, NY). The passed-
through fibroblasts/myofibroblasts were cultured in DMEM with 10% FBS until grown to 100% 
confluency, and then were stored in liquid nitrogen for further use.  
2.14 Construction of shRNA vector 
We used BLOCK-iT RNAi Designer, an online software from Thermofisher.com to 
design oligonucleotides for EZH2 shRNAs, The highest ranked target sequence, 
GCAGCTTTCTGTTCAACTTGA, was chosen. For the forward (FW) oligo, GATCC, a 
sequence for BamH1 restriction enzyme was added to the 5’ of the target sequence. 
TTCAAGAGA, a loop sequence, was added to the 3’ followed by antisense sequence. TTTTTG 
was added to the 3’ end of the oligo. The final sequence was 
GATCCGCAGCTTTCTGTTCAACTTGATTCAAGAGATCAAGTTGAACAGAAAGCTGTT
TTTG. For the reverse (RE) oligo, AATTCAAAA, a sequence for EcoR1 restriction enzyme was 
added to the 5’ of the target sequence. Loop sequence, TCTCTTGAA, was added between the 
target sequence and the antisense sequence. Another G was added to the 3’ end. The final 
sequence was 
AATTCAAAAAGCAGCTTTCTGTTCAACTTGATCTCTTGAATCAAGTTGAACAGAAAG
CTGG. FW and RW oligo was annealed in annealing buffer (Promega, Madison, WI).  
pGreenPuro vector (System Biosciences, Mountain View, CA) was first double-digested 
using BamH1 and EcoR1 restriction enzymes. The annealed oligo then was ligated with the 
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digested pGreenPuro vector using T4 ligase (Promega, Madison, WI). The plasmids were 
transformed and amplified in competent cells (E. Coli ST3). The final plasmids were isolated 
using the QIAprep Spin Miniprep Kit (Qiagen, Valencia, CA). The sequence of the insert was 
confirmed by sequencing.  
2.15 Preparation of lentivirus and titer determination 
HEK293T cells were seeded in 100 mm cell culture dishes and cultured in 37°C 
incubator with 5% CO2 and 95% air overnight. The medium was replaced with 9 ml of Opti-mem 
medium containing 4% fetal bovine serum (FBS). The culture dishes were put back to an 
incubator. Meanwhile, 1.5 ml of Opti-mem medium was gently mixed with 3 µg of 
shRNA/control plasmid and 9 µg of Lenti-X HTX packaging mix (Clontech, Mountain View, 
CA). Another 1.5 ml of Opti-mem was gently mixed with 36 µl of Lipofectamine 2000 (Thermo 
Fisher Scientific, Grand Island, NY). After incubating at room temperature for 5 minutes, the two 
mixtures were mixed and incubated for 20 minutes at room temperature. 3 ml of the final mixture 
wad added into each dish and cultured overnight. The medium was then replaced with full growth 
medium (DMEM with 10% of FBS and 1% of penicillin-streptomycin).  After 24 hours, the 
medium containing lentiviruses was centrifuged at 1,000 g for 15 minutes at 4°C, aliquoted into 1 
ml per tube, and stored at -80°C until use.  
To determine the lentivirus titer, 1 ml of HEK293T cells (5×105 cells/ml) was seeded in 
each well of 12-well plates and cultured for 24 hours. 500 µl of 1,000 times diluted in full growth 
medium were added into each well, and incubated for 24 hours. Green fluorescent protein (GFP) 
positive cells were counted under a 20X objective using a fluorescent microscope for ten random 
fields. The titer was calculated as mean (GFP positive cells) x 594 (fields)/0.5 ml x 10-3 (IU/ml). 
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2.16 Infection of cells with shRNA lentivirus 
1 x 105 of LL29 cells were seeded in each well of 12-well plates and cultured overnight 
in 1 ml of full growth medium in an incubator. The lentiviruses were then added at a multiplicity 
of infection (MOI) of 100. Polybrene (1:200) was also added into the medium to increase the 
efficiency of infection. 24 hours after infection, the virus medium was replaced with full growth 
medium. After another 24 hours, cells were treated with 5 ng/ml of TGFβ1 for 24 hours.  
2.17 Co-Immunoprecipitation (Co-IP) 
LL29 cells were treated with DZNep for 48 hours and stimulated with 5 ng/ml of TGFβ1 
for 60 minutes. The cells were lysed using M-PER mammalian protein extraction lysis buffer for 
30 minutes on a rocker at 4°C. The lysate was centrifuged at 12,000 rpm for 15 minutes at 4°C. 
The supernatant was transferred to a tube and stored at -80°C. Protein concentration was 
determined using DC protein assay.  220 µg of cell lysate was taken to a fresh tube, and made to a 
total volume of 220 µl using lysis buffer. 200 µl of the lysate was transferred to fresh tubes and 
was incubated on ice with anti-EZH2 antibodies (1:50) for one hour on ice. 20 µl of protein A/G 
beads was added into the lysate. The mixture was rotated at 4°C overnight and centrifuged at 
10,000 rpm for 7 minutes at 4°C. The supernatant was transferred to fresh tubes and saved as “out” 
fraction. The remaining pellet (beads) was washed with 1 ml of PBS for 4 times. 80 µl of 1X 
protein loading buffer were added and boiled for 7 minutes. 20 µl of each sample were taken for 
western blotting using anti-EZH2 and anti-Smad2/3 antibodies. 
2.18 Phosphorylation of Smad2/3 
LL29 cells were treated with DZNep for 48 hours, and then with 5 ng/ml of TGFβ1 for 0, 
30, 60 and 120 minutes. Cells were lysed using M-PER mammalian protein extraction lysis buffer 
with proteinase and phosphatase inhibitors (1:100) for 30 minutes on a rocker at 4°C. The lysate 
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was centrifuged at 12,000 rpm for 15 minutes at 4°C. The supernatant was transferred to a tube 
and stored at -80°C until use. Protein concentration was determined using DC protein assay. 
Western blotting was performed using anti-phospho-Smad2/3 primary antibodies and total 
Smad2/3 antibodies.  
2.19 Mouse model of pulmonary fibrosis 
Ten-week old female C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) were 
housed in the Animal Resources at Center for Veterinary Health Sciences, Oklahoma State 
University. The animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the Oklahoma State University. Mice were anesthetized using Ketamine 
and Xylazine mixture through intraperitoneal injection. The mice were then challenged with 50 µl 
of PBS or 1 unit/kg of bleomycin (Sigma-Aldrich, St. Louis, MO) in 50 µl PBS through an 
intratracheal route. EZH2 inhibitor DZNep (2 mg/kg) in 300 µl PBS was given every day through 
intraperitoneal route beginning 1 day before bleomycin instillation until day 17. Lung tissues 
were collected on day 17 after bleomycin challenge. The right lung was fixed with 4% 
formaldehyde for H&E staining and immunostaining. The left lung was minced, and then 
grounded into powder in liquid nitrogen, half of the sample was homogenized using Tri Reagent 
for real-time PCR and another half was homogenized using M-PER protein lysis buffer for 
Western blotting. The severity of pulmonary fibrosis was evaluated by Ashcroft scores according 
to the method of Ashcroft [115].   
2.20 Statistical analysis 
Statistical analyses were performed using Student’s t-test for two independent groups and 
one-way ANOVA, followed by Tukey’s post hoc test or two-way ANOVA, followed by 
Bonferroni’s post hoc test for multiple comparisons. P < 0.05 was considered significant. 
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CHAPTER III 
 
 
RESULTS 
3.1 miR-424 induces myofibroblast differentiation during Epithelial-to-Mesenchymal 
Transition 
3.1.1 TGF-β1 reduces epithelial cell marker expression and increases mesenchymal cell 
marker expression 
In order to investigate the role of miRNAs in EMT, we used a TGF-β1-induced EMT cell 
model [107]. We treated human lung epithelial A549 cells with 5 ng/ml of TGF-β1 for 4, 8, or 12 
days, and determined epithelial and mesenchymal cell mRNA marker expression. E-cadherin 
(CDH1), an epithelial marker, was down-regulated in a time-dependent manner. It dramatically 
decreased on day 4 and was barely detectable on day 12 (Fig. III.1.1A). N-cadherin (CDH2), a 
mesenchymal marker, was increased on day 4, peaked on day 8 and returned to the day 4 level by 
day 12 (Fig. III.1.1B). α-smooth muscle actin (α-SMA), a myofibroblast marker, was marginally 
increased on day 8 (Fig. III.1.1C), consistent with a previous report [107]. These results indicate 
that TGF-β causes EMT, but is not sufficient for myofibroblast differentiation.  
We further examined genes that encode key transcription factors in the TGF-β signaling 
pathway. We found that mRNA for ZEB1, a repressor of epithelial genes, peaked on Day 8 (Fig. 
III.1.2A). However, SIP1, another repressor of epithelial genes, was not significantly affected at  
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any time point by TGF-β (Fig. III.1.2B). Among other transcription factors in the TGF-β 
signaling pathway which were tested, Snail2 mRNA showed the greatest increase by TGFβ, while 
Id2 (an inhibitor of the E-cadherin repressor, E2A) showed the greatest decrease (Fig. III.1.2C). 
 
Fig. III.1.1. TGF-β1 induces EMT in human alveolar epithelial cells. Human A549 cells were treated with TGF-β1 
(5 ng/ml) for 4, 8 and 12 days (D4, D8 and D12). The mRNA expressions of the cell markers were determined by real-
time PCR. (A) Epithelial cell marker, E-cadherin (CDH1). (B) Mesenchymal cell marker, N-cadherin (CDH2). (C) 
Myofibroblast marker, α-smooth muscle actin (α-SMA). Results were normalized to 18S rRNA and expressed as a ratio 
of the TGF-β1 treated group to the control group at each time point. Results are means ± s.e. from the three 
independent experiments, which were performed in triplicate.  *P<0.05 v.s. without TGF-β1; **P<0.01 v.s. without 
TGF-β1; ***P<0.001 v.s. without the TGF-β1. Student’s t-test.  
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Fig. III.1.2. Effects of TGF-β on transcription factors. A549 cells were treated with TGF-β1 (5 ng/ml) for 4, 8 and 
12 days (D4, D8 and D12). The mRNA levels of ZEB1 (A) and SIP1 (B) were measured by real-time PCR and 
expressed as a ratio of the TGF-β1 treated group to the control group at each time point.  The mRNA levels of E2A, 
Id2, ID3, Snail1, Snail2, and Twist on day 8 after TGF-β1 were also determined by real-time PCR and expressed as 
delta delta CT (C). Data were normalized to 18S rRNA. Results are means ± s.e. from the three independent 
experiments, which were performed in triplicate.  *P<0.05 v.s. without TGF-β1; **P<0.05 v.s. without TGF-β1. 
Student’s t-test. 
 
3.1.2 Six miRNAs are up-regulated and three miRNAs are down-regulated during EMT 
Since the mesenchymal cell marker, CDH2, and the transcription factor, ZEB1, peaked 
on day 8 of TGF-β1 treatment, we chose this time point for miRNA microarray analysis as 
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described in our previous studies [111, 112, 116], with a goal of identifying miRNAs involved in 
the process of EMT. We used in-house printed miRNA microarray slides containing 1,700 
miRCURY LNA probes for human, rat and mouse miRNAs (EXIQON). After quality control and 
statistical analysis, six miRNAs were found to be up-regulated, while nine miRNAs were down-
regulated. Since miRNA microarray is semi-quantitative [82], we used real-time PCR to verify 
the miRNA microarray data. We verified 9 miRNAs, including 6 up-regulated (miR-31, miR-190, 
miR-424, miR-136-3p, miR-487a and miR-582-5p) and 3 down-regulated (miR-1224-3p, miR-
23b-5p and miR-933) miRNAs (Fig. III.1.3).  
 
Fig. III.1.3 miRNAs changed during EMT. A549 cells were treated with 5 ng/ml of TGF-β1 for 8 days. miRNA 
microarray and real-time PCR were performed to identify the miRNAs changed during EMT.  All real-time PCR data 
were normalized to RNU6B small RNA. The results were expressed as log2 ratio (TGF-β1-treated vs control). Data 
shown are means ± s.e. All microarray and real-time PCR results were statistically significant (P<0.05). n=3 cell 
preparations. Student’s t-test.  
 
 
	 	
	
30	
	
3.1.3 Over-expression of miR-424 promotes myofibroblast differentiation 
We designed two experiments to test whether the identified 9 miRNAs affected EMT. If 
TGF-β1-mediated EMT is due to the down-regulation of inhibitory miRNAs, the over-expression 
of these down-regulated miRNAs should inhibit TGF-β1-induced EMT. On the other hand, if the 
up-regulated miRNAs during EMT cause EMT, the over-expression of these miRNAs should 
mimic the effect of TGF-β1 treatment. We over-expressed the 3 down-regulated miRNAs in 
A549 cells using lentiviral miRNA expression vectors, treated the cells with TGF-β1, and 
determined the epithelial and mesenschymal cell marker expression. Real-time PCR analysis 
revealed that over-expression of those miRNAs had no effect on the expression of the epithelial 
marker CDH1 (Fig. III.1.4A) compared to the virus control.  However, expression of the 
mesenchymal marker CDH2 was increased by 2 of the 3 miRNAs tested (miR-1224-5p and miR-
23b), which was an effect opposite to that expected if these miRNAs have a role in EMT (Fig. 
III.1.4B). Furthermore, miR-23b and miR-933 also slightly increased α-SMA expression (Fig. III. 
1.4C). These results suggest that the 3 down-regulated miRNAs tested are likely not involved in 
EMT. 
Next, we overexpressed the 6 up-regulated miRNAs in A549 cells without TGF-β1 
treatment to see whether they could induce EMT. miR-136, miR-190, miR-31 and miR-424 had 
no effect on either the CDH1 or CDH2 expression (Fig. III. 1.4D, E). In contrast, miR-487a and 
miR-582 increased both epithelial (CDH1) and mesenchymal (CDH2) marker expression. This is 
not consistent with EMT, in which epithelial cell markers are decreased and mesenchymal cell 
markers are increased. However, miR-424 significantly increased α-SMA expression (Fig. III. 
1.4F).  
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Fig. III.	1.4 Effect of over-expressing miRNAs on the expression of epithelial cell marker and mesenchymal cell 
markers. A549 cells were infected with a miRNA lenti-virus at a MOI of 50 for 2 days and then treated with TGF-β1 
(5 ng/ml) (A-C) or nothing (D-F) for 3 days. mRNA levels of CDH1, CDH2 and α-SMA were measured by real-time 
PCR and normalized to 18S rRNA.  Results are means ± s.e. (two cell preparations, measured in duplicate), except 
miR-424 which had 5 cell preparations. *p<0.05 v.s. VC. BC: Blank control, VC: Virus control. 
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Fig. III.	1.5 Over-expression of miR-424 promotes myofibroblast differentiation during EMT. A549 cells were 
infected with miR-424 lentivirus at a MOI of 50 for 24 h, followed by TGF-β1 treatment (5 ng/ml) for 72 h. miR-424 
and mRNA expressions were determined using real-time PCR. (A) miR-424, (B) CDH1, (C) CDH2, (D) α-SMA, (E) 
CTGF, and (F) FN. miR-424 expression was normalized to RNU6B, while mRNA expression was normalized to 18S 
rRNA. BC: Blank control, VC: Virus control, CTGF: Connective tissue growth factor, FN: Fibronectin. Results are 
means ± s.e. (n=3). *P<0.01 v.s. VC. #P<0.05 v.s. non-TGFβ1 treated control. Two-way ANOVA with Bonferroni 
post-test. 
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We further examined the effects of miR-424 on the myofibroblast differentiation during 
TGF-β1-induced EMT. The miR-424 level was increased by 25 fold when A549 cells were 
treated with a miR-424 lentivirus (Fig. III. 1.5A). TGF-β1 further increased the miR-424 level in 
the miR-424 lentivirus-treated cells. While TGF-β1 decreased CDH1 and increased CDH2 
mRNA expression, miR-424 had no effect on CDH1 or CDH2 mRNA expression in either the 
presence or the absence of TGF-β1 (Fig. III. 1.5B, C). However, over-expression of miR-424 
increased α-SMA mRNA expression. The combination of miR-424 over-expression with TGF-β1 
treatment further increased α-SMA expression compared to TGF-β1 or miR-424 over-expression 
alone (Fig. III. 1.5D). The same effects were observed for connective tissue growth factor 
(CTGF), another myofibroblast marker (Fig. III. 1.5E). Although miR-424 overexpression alone 
had no effect on the fibronectin (FN) mRNA level, the combination of TGF-β1 and miR-424 
over-expression increased FN expression (Fig. III. 1.5F). The results suggested that miR-424 may 
enhance myofibroblast differentiation, but not EMT.  
3.1.4 miR-424 enhances activity of the TGF-β signaling pathway 
 Since miRNAs form many positive and negative regulatory loops, and miR-424 is 
regulated by TGF-β signaling, we examined whether miR-424 affects the activity of the TGF-β 
pathway using a TGF-β reporter luciferase assay. TGF-β1 increased the reporter activity in the 
vector control group. miR-424 alone enhanced the reporter activity to almost the same level as 
that in the TGF-β1-treated vector control group (Fig. III. 1.6). The combination of miR-424 over-
expression and TGF-β1 stimulation further increased the reporter activity. This result indicates 
that miR-424 potentiates the TGF-β signaling pathway.  
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Fig. III.	1.6 miR-424 increases TGF-β signaling activity. HEK 293T cells were co-transfected with 50 ng of the 
TGF-β signaling reporter plasmid and 100 ng of miR-424 expression plasmid by using Lipofectamine. After 24 h of 
incubation, the cells were treated with TGF-β1 (5 ng/ml) for 24 h and assayed for dual-luciferase activities. The results 
shown are mean ± s.e. (n=3). *P<0.001 v.s. vector control (VC). #P<0.001 v.s. non-TGF-β1 treated control. 
3.1.5 Smurf2 is a target of miR-424 
Since miRNAs negatively regulate their target genes, we would expect that miR-424 
targets negative regulators in the TGF-β signaling pathway to enhance TGF-β signaling activity. 
Using Web-based target predication software (TargetScan, miRand and DIANA-microT), we 
identified three negative regulators of the TGF-β/Smad signaling (Smad7, Smurf1 and Smurf2) as 
potential targets of miR-424 (Table III.1). To verify the prediction, we first used a 3’-UTR 
reporter assay in HEK293 cells. As shown in Fig. III. 1.7A, miR-424 inhibited the 3’-UTR 
reporter activities of Smad7, Smurf1 and Smurf2. Since miRNA-mediated effects may be cell 
content-dependent, we further studied whether miR-424 could reduce the endogenous expression 
of these proteins in A549 cells. We increased the miR-424 expression level in A549 cells using a 
miR-424 lentivirus at a MOI of 50. Western blotting revealed that the Smurf2, but not Smurf1 or 
Smad7 protein levels, was significantly decreased in the miR-424-over-expressed cells in 
comparison with virus control or blank control groups (Fig. III. 1.7B, C). The mRNA expression 
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levels of the three predicted targets were not affected by miR-424 (Fig. III. 1.7D), suggesting that 
miR-424 directly inhibits protein translation of Smurf2.   
 
 
Fig. III.	1.7 Effects of miR-424 on the expression of Smurf2. (A) 3’-UTR reporter assay. 3’-UTR reporter plasmids 
of Smad7, Smurf1 or Smurf2 were co-transfected with a miR-424 expression vector, or its control vector (Con), into 
HEK293 cells. The dual luciferase activities were measured and expressed a ratio of firefly to Renilla luciferase activity. 
The results were normalized to the empty vector control without 3’-UTR (EVC) from the two independent experiments, 
each with 3 replications. *P<0.005 v.s. control. (B-D) A549 cells were infected with a miR-424 lentivirus at a MOI of 
50 for 48 h. Protein and mRNA levels of Smad7, Smurf1 and Smurf2 were determined using Western blotting and real-
time PCR. (B) Western blot showed the protein expressions of Smurf1, Smurf2 and Smad7. GAPDH was used as a 
loading control. (C) The quantitation of protein levels from Western blotting using Image J. Data was normalized to 
GAPDH. (D) mRNA levels of Smurf1, Smurf2 and Smad7 were determined by real-time PCR and normalized to 18S 
rRNA. BC: Blank control, VC: Virus control. The results shown are means ± s.e. (n=3). *P<0.05 v.s. VC. Two-way 
ANOVA with bonferroni post-test. 
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Table III.1: Predicated binding sites of miR-424 
	 Smad7 Smurf1 Smurf2 
miRRanda 42-62 2904-2925 210-232 
TargetScan 6.2 55-62 2918-2925 (conserved) 
451-457 (poorly conserved) 
225-231 
DIANA microT 3.0 33-61 2896-2924 
931-959 
1368-1396 
N/A 
 
 
3.2 EZH2 enhances myofibroblast differentiation in idiopathic pulmonary fibrosis 
3.2.1 EZH2 is up-regulated in the lungs of patients with IPF and mice with bleomycin-
induced lung fibrosis.  
 To determine the potential roles of EZH2 in IPF, we first measured the EZH2 mRNA 
expression in the lung tissues of patients with IPF. The tissues were divided into three groups by 
the disease severity according to patients’ pulmonary function, which was determined by the 
predicted forced vital capacity (FVC): mild group,  > 80%; medium group, 50% - 80% ; and 
severe group,  < 50%. We found that the mRNA expression of EZH2 increased in a fashion of a 
positive correlation with the severity of the disease (Fig. III.2.1). Both 50% - 80% and < 50% 
groups had a statistically significant increase in EZH2 mRNA expression compared to > 80% 
group. EZH2 mRNA expression was the lowest in patients with a FVC of > 80% and was the 
highest in patient with a FVC of < 50%.  
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Figure III.2.1: EZH2 expression in the lungs of patients with IPF. Lung tissues from patients with IPF were 
grouped according to their forced vital capacity (FVC): mild, > 80% (8 patients), medium, 50% - 80% (10 patients), 
and severe, < 50% (10 patients). The mRNA expression of EZH2 was determined by real-time PCR and normalized to 
β-actin. The results shown are means ± SE. *P < 0.05 vs. > 80% FVC group (Student T-test). 
We also examined the EZH2 expression in the lung tissues of a bleomycin-induced 
murine lung fibrosis model. Immunohistochemical analysis using EZH2 antibodies showed a 
strong staining in the bleomycin group whereas signals could be barely detected in the control 
group (Fig. III.2.2A), suggesting that EZH2 protein is also up-regulated in bleomycin-induced 
lung fibrosis. 
To determine whether the increase in EZH2 protein occurs in myofibroblasts, we 
performed double-labeling with antibodies against EZH2 and α-SMA, a cellular marker for 
myofibroblasts.  We used ABC staining to detect EZH2 protein and immunofluorescence staining 
to detect α-SMA protein on the same slide. Positive signals for EZH2 (brown) and α-SMA (green) 
were observed in the fibrotic foci of lungs from bleomycin-challenged mice. When the images 
from both staining were overlaid, EZH2 and α-SMA signals were found to be co-localized in the 
same cells (Fig. III.2.2B). To further confirm this finding, we isolated primary 
fibroblasts/myofibroblasts from the lungs of mice challenged with bleomycin or PBS (control). 
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Western blot analysis revealed that EZH2 protein was increased in the fibroblasts/myofibroblasts 
from bleomycin-challenged mice comparing to these from control mice (Fig. III.2.2C).  
 
Figure III.2.2: EZH2 expression in the lungs of bleomycin-challenged mice. (A) Lung tissue sections of PBS- 
(control) and bleomycin-challenged mice were stained with anti-EZH2 antibodies and ABC staining. EZH2 was shown 
as brown color. Scale bars: left, 100 µm and right, 50 µm. (B) Lung tissue sections were double-labeled with ABC 
staining using anti-EZH2 antibodies and immunofluorescence staining using anti-α-SMA antibodies. Nuclei were 
stained with DAPI. Overlay of EZH2 and α-SMA stainings showed co-localization of two proteins. Scale bar: 50 µm. 
(C) Primary fibroblasts/myofibroblasts were isolated from PBS control and bleomycin-challenged mice. EZH2 protein 
levels were determined by western blotting. Quantitation of western blot results was performed using Image J software 
and normalized to GADPH. The results shown are means ± SE from 3 independent experiments, in which each 
experiment used different generations of primary fibroblasts/myofibroblasts from 4 animals (2 control and 2 
bleomycin-challenged mice). *P < 0.05 (Student T-test).   
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3.2.2 EZH2 is required for the TGFβ1-induced differentiation of fibroblasts to 
myofibroblasts. 
 To determine the function of EZH2 in IPF, we examined the effect of EZH2 inhibition on 
the differentiation of fibroblasts to myofibroblasts. We used the EZH2 inhibitor 3-
Deazaneplanocin A (DZNep) for this purpose. DZNep inhibits S-adenosylhomocystine (AdoHcy) 
hydrolase, which leads to the accumulation of AdoHcy. An increased level of AdoHcy inhibits 
the EZH2 protein level in cells [117-121]. Human lung fibroblasts (LL29) were treated with 
DZNep and then stimulated with TGFβ1. Western blot analysis showed that TGFβ1 had no 
effects on EZH2 protein expression. However, DZNep reduced the EZH2 protein level in both 
basal and TGFβ1-stimulated cells (Fig. III.2.3A, B). TGFβ1 increased mRNA and protein 
expression of α-SMA and the reduction of EZH2 level by DZNep inhibited the TGFβ1-induced 
α-SMA (Fig. III.2.3A, C, D). Furthermore, the mRNA levels of fibronectin (FN) and COLA4A1, 
the markers of fibroblast activation, was also induced by TGFβ1, but was inhibited by DZNep 
(Fig. III.2.3 E, F).  
 Contractility is one of the characteristics of fibroblasts/myofibroblasts and myofibroblasts 
have a stronger contractility compared to fibroblasts [72]. We measured contractility using a gel 
contraction assay [122, 123]. LL29 cells were pre-treated DZNep, followed by TGFβ1 
stimulation. The cells were trypsinized and mixed with collagen. After polymerization, the gels 
were detached from the bottom of the wells. Cell contractility causes the shrinkage of the gel (Fig. 
III.2.4A) and thus the surface area of the gel reflects cell contractility. TGFβ1-treated cells 
showed a smaller surface area comparing to these without TGFβ1 treatment. The inhibition of 
EZH2 by DZNep significantly increased the gel surface area in both basal and TGFβ1-stimulated 
cells (Fig. III.2.4B), indicating that DZNep reduced fibroblasts/myofibroblasts contractility.  
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Figure III.2.3: TGFβ1-induced myofibroblast marker expression is inhibited by EZH2 inhibitor DZNep. LL29 
cells were treated with DZNep (4 µM) for 24 hours and then with DZNep and TGFβ1 (5 ng/ml) together for additional 
24 hours. The cells without DZNep treatment was used as a control (CON). EZH2 and α-SMA protein expression was 
measured using western blotting. GAPDH was used as a loading control. Representative blots are shown in (A) and 
quantitation results using ImageJ software were normalized to GAPDH and are shown in (B) and (C). The mRNA 
levels of α-SMA (D), fibronectin (FN) (E) and COL4A1 (F) were determined using real-time PCR and normalized to β-
actin.  All the results are means ± SE from three independent experiments, each performed in duplication. *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001, (ANOVA and Fisher’s LSD).  
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Figure III.2.4: TGFβ1-induced contractility is inhibited by EZH2 inhibitor DZNep. (A) LL29 cells were treated 
with DZNep (4 µM) for 24 hours and then with DZNep and TGFβ1 (5 ng/ml) together for additional 24 hours. The 
cells were mixed with Collagen 1 and added to 12-well plates. Gel was detached from well wall and bottom and the 
images were taken after 48 hours. (A) Representative images. (B) Gel surface area was measured using Image J 
software. Results shown are means ± SE from three independent experiments (n = 3) with duplication in each 
experiment. ** P < 0.01 (ANOVA and Fisher’s LSD). 
 
To further confirm the inhibitor study, we reduced EZH2 protein level using gene 
silencing. LL29 cells were infected with EZH2 shRNA or control lentivirus at a MOI of 50 and 
then stimulated the cells with TGFβ1. Western blot analysis showed a reduction in EZH2 and α-
SMA protein level in the EZH2 shRNA-treated cells (Fig. III.2.5A, B). Taken all together, our 
results suggest that the reduction of EZH2 level inhibits the differentiation of fibroblasts to 
myofibroblasts. 
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Figure III.2.5: EZH2 knock-down decreases myofibroblast marker α-SMA. LL29 cells were infected with a 
lentivirus containing shEZH2 or its control shCON at a MOI of 100 for 24 hours. 48 hours after infection, the cells 
were treated with 5 ng/ml of TGFβ1 for another 24 hours. EZH2 and α-SMA protein levels were determined by 
western blotting. (A) Representative blots. (B, C) Quantitation of western blotting results using Image J software. The 
results were normalized to GAPDH and expressed as a percent of shCON. Data shown are means ± SE from three 
independent experiments, each performed in duplicate. ***P < 0.001 (Student T test). 
3.2.3 EZH2 inhibition reduces p-Smad2/3 nuclear translocation via its interaction with 
Smad2/3. 
 TGFβ signaling is initiated by the binding of TGFβ to the complex of transmembrane 
receptor serine/threonine kinases (TβRI and II) on cell membrane. The activated TβRI 
phosphorylates Smad2/3, which form a complex with Smad4. The Smad complex then 
translocates into the nucleus and regulates the transcription of down-stream target genes. To 
explore how EZH2 affects TGFβ signaling, we first determined whether DZNep affects the 
phosphorylation of Smad2/3. LL29 cells were treated with DZNep for 48 hours and then 
stimulated with TGFβ1 for 30, 60 and 120 minutes. TGFβ treatment resulted in the 
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phosphorylation of Smad2/3 as determined by western blotting using antibodies against 
phosphorylated Smad2/3. However, DZNep had little effect on the phosphorylation of Smad2/3 
(Fig. III.2.6).  
 
Figure III.2.6: Phosphorylation of Smad2/3 is not affected by DZNep. LL29 cells were treated with 4 µM of 
DZNep for 48 hours and then with TGFβ1 (5 ng/ml) for 30, 60 or 120 minutes. Western blotting was performed to 
detect the protein levels of EZH2, p-Smad2/3, Smad 2/3 and β-actin. Representative results are shown from three 
independent experiments. 
 We next determined whether DZNep affects p-Smad2/3 nuclear translocation. LL29 cells 
were treated with DZNep for 48 hours and stimulated with TGFβ1 for 60 minutes. The nucleus 
was separated from cytosol. Sole localizations of cytoplasmic marker GAPDH in cytosol and 
nuclear marker lamin B1 in nucleus confirmed the separation of nuclear and cytosol (Fig. III.2.7). 
EZH2 was only located in the nucleus and its protein level was reduced by DZNep treatment. p-
Smad2 and p-Smad3 were only detected in the TGFβ1-treated group, in which DZNep decreased 
the level of p-Smad2/3 in nucleus, but increased them in cytosol. This result indicates that the 
inhibition of EZH2 reduces p-Smad2/3 nuclear translocation.  
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Figure III.2.7: DZNep inhibits phospho-Smad2/3 nuclear translocation. LL29 cells were treated with DZNep (4 
µM) or none (CON) for 48 hours and then with TGFβ1 (5 ng/ml) for 60 minutes. Protein levels of EZH2, p-Smad 2, p-
Smad3 and Smad 2/3 in cytoplasmic and nuclear fractions were determined by Western blotting. GAPDH and lamin B1 
were used as cytosol and nucleus loading controls. Representative results were shown from three independent 
experiments. 
EZH2 has binding motifs which could interact with other protein molecules. We reasoned 
that EZH2 could directly interact with Smad2/3 in nucleus, resulting in the increased p-Smad2/3 
nuclear translocation by retaining them in the nucleus. To test this hypothesis, we performed a 
Co-immunoprecipitation (Co-IP) experiment to detect a physical interaction between EZH2 and 
Smad2/3. LL29 cell lysates were immunoprecipitated with anti-EZH2 antibodies and the complex 
was detected for Smad2/3 by western blotting.  Most of the EZH2 was pulled-down with anti-
EZH2 antibodies and Smad2/3 were detected in the immunoprecipitates (Fig. III.2.8). Since 
DZNep reduces EZH2 protein expression, less EZH2 and Smad2/3 was observed in the 
immunoprecipitates. The result suggests an interaction between EZH2 and Smad2/3.  
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Figure III.2.8: EZH2 directly interacts with Smad2/3. LL29 cells were pre-treated with 4 µM of DZNep for 24 
hours and then with 5 ng of TGFβ1 and 4 µM of DZNep for another 24 hours. The cell lysates were 
immunoprecipitated with anti-EZH2 antibodies. EZH2 and Smad2/3 in the complex were determined by western 
blotting.  Representative results were shown from three independent experiments. IN: total cell lysate; IP: pulled-down 
protein; OUT: cell lysate after pull-down. 
3.2.4 DZNep attenuates the severity of bleomycin-induced lung fibrosis  
 To determine the in vivo effect of EZH2 inhibition on lung fibrosis, we delivered DZNep 
to mice daily starting one day before bleomycin challenge through intraperitoneal route. Lung 
tissues were collected on day 17. Bleomycin increased the mRNA expression of EZH2 by 10-fold 
compared to PBS group (6.96 ± 1.46×10-6 vs. 6.98 ± 3.54×10-5), and DZNep treatment 
attenuated the increase by 77% (Fig. III.2.9A). Similar changes were observed for EZH2 protein 
with a 10.8-fold increase in the bleomycin group compared to control group and a 73% inhibition 
by DZNep (Fig. III.2.9B). This result confirmed the effectiveness of DZNep treatment in vivo in 
reducing EZH2 expression levels.   
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Figure III.2.9: DZNep inhibits bleomycin-induced EZH2 mRNA and protein expression in mice. Female 
C57BL/6 mice were challenged with PBS or bleomycin intratracheally and treated with PBS or DZNep through 
intraperitoneal injection once per day starting on one day before bleomcyin challenge. Left lung tissue was collected on 
day 17. (A) mRNA level of EZH2 was determined using real-time PCR and normalized to 18S rRNA. EZH2 protein 
level was determined by western blotting. Representative blots and quantitation were shown in (B). The results were 
normalized to GAPDH. Data shown are means ± SE. n = 6 animals in each group *P < 0.05, **P < 0.01, *** P < 0.001, 
**** P < 0.0001 (ANOVA and Fisher’s LSD).  
H & E staining showed that while the lung tissue of mice was normal in both PBS and 
DZNep group, there were thickened alveolar septa and fibroblasts/myofibroblasts foci found in 
the lung tissue of bleomycin-treated mice. The lungs of the bleomycin plus DZNep group 
exhibited a marked reduction in fibrotic areas (Fig. III.2.10A). The severity of fibrosis then was 
evaluated using a semi-quantitative histological scoring system introduced by Ashcroft [115]. 
Generally, a higher Ashcroft score represents more severe fibrosis histologically. Ashcroft scores 
in PBS and DZNep groups were zero. In the bleomycin-challenged group, the Ashcroft score was 
5.09 ± 0.27, which was reduced to 3.43 ± 0.64 by DZNep treatment (Fig. III.2.10B).  
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Figure III.2.10: DZNep attenuates pulmonary fibrosis histologically. Female C57BL/6 mice were challenged with 
PBS or bleomycin intratracheally and treated with PBS or DZNep through intraperitoneal injection once per day 
starting on one day before bleomcyin challenge. Right lung tissue was collected on day 17 and stained with 
hematoxylin and eosin. (A) Representative images. Scale bar: 200 µm. (B) Ashcroft scale system was used to quantify 
pulmonary fibrosis. All the results are means ± SE. n = 6 animals in each group. *P < 0.05 (Student T-test).  
To further assess the severity of lung fibrosis in each group, we measured mRNA and/or 
protein expression of myofibroblast markers. The mRNA level of α-SMA, as expected, was up-
regulated by 73% using bleomycin challenge (7.61 ± 1.62 ×10-5  vs. 13.2 ± 0.2 ×10-5) and this 
increase was decreased 37% by DZNep treatment (Fig. III.2.11A). Similar changes were 
observed for the mRNA expression of COL1A1 and COL3A1 (Fig. III.2.11B, C). α-SMA protein 
was also up-regulated in the bleomycin-treated group and down-regulated by DZNep treatment 
(Fig. III.2.11D). All the results suggest that DZNep reduces the severity of bleomycin-induced 
fibrosis in the lungs. 
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Figure III.2.11: DZNep inhibits fibrotic markers in mice lungs. Female C57BL/6 mice were challenged with PBS 
or bleomycin intratracheally and treated with PBS or DZNep through intraperitoneal injection once per day starting on 
one day before bleomcyin challenge. Left lung tissue was collected on day 17. The mRNA levels of fibrotic markers α-
SMA (A), COL1A1 (B), and COL3A1 (C) were determined using real-time PCR and normalized to 18S rRNA. α-
SMA protein level was determined using western blotting. Representative blots and quantitation were shown in (B). 
The results were normalized to GAPDH. All the results are means ± SE. n = 6 animals in each group. *P < 0.05, **P < 
0.01, **** P < 0.0001 (ANOVA and Fisher’s LSD).  
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CHAPTER IV 
 
 
DISCUSSION 
 
4.1 miR-424 and EMT 
The purpose of this study was to identify specific miRNAs that have roles in EMT during 
IPF.  First, we identified 6 up-regulated and 3 down-regulated miRNAs in the TGF-β-induced 
EMT model of human lung epithelial cells through miRNA microarray analysis. One of these up-
regulated miRNAs, miR-424, enhanced the expression of α-SMA without affecting epithelial or 
mesenchymal cell markers. miR-424 also increased the activity of the TGF-β signaling pathway 
and decreased the protein expression of Smurf2, a negative regulator of TGF-β signaling. Our 
results suggest that miR-424 regulates the myofibroblast differentiation during EMT by 
potentiating the TGF-β signaling pathway, likely through Smurf2.  
miRNAs have been reported to regulate EMT in a variety of cell lines. Previous studies 
have shown that the miR-200 family and miR-205 are gradually down-regulated during TGF-β1-
mediated EMT. The manipulation of their levels affects EMT in renal epithelial cells by targeting 
ZEB1 and SIP1 [87].  The miR-200 family is also down-regulated in IPF patients, and regulates 
EMT in rat alveolar epithelial cells (AECs) [124]. A number of other miRNAs have also been 
reported to be involved in lung fibrotic diseases, including miR-21, miR-155, miR-29 and let-7d 
[86, 88, 90-92]. However, direct miRNA microarray analysis of EMT in lung epithelial cells has 
not been reported yet. In this study, we identified 9 miRNAs which were changed during EMT of  
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the lung epithelial cells. Among these 9 miRNAs, only miR-31 has been shown to have a role in 
EMT by inhibiting the activation of lung fibroblasts through directly targeting integrin α(5) and 
RhoA [124]. 
The changes in miRNAs during EMT do not necessarily mean that the altered miRNAs 
have functional roles in EMT. Indeed, using the gain-of-function approach, we found that only 
miR-424 markedly increased α-SMA expression. α-SMA is considered to be a marker for 
myofibroblasts and an indicator for myofibroblast differentiation [90, 125, 126]. In lung fibrotic 
diseases, the persistence of myofibroblasts is an important indicator of the end stage of the 
disease [72, 127, 128]. Myofibroblasts have stronger contractile activity and are more responsive 
to inflammatory factors than fibroblasts [129]. Thus, the increase in myofibroblasts in the 
diseased lung may reduce lung compliance, enhance extracellular matrix production, disrupt the 
basement membrane and cause inflammation and epithelial injury [44, 130]. It is still not clear 
what causes myofibroblast differentiation. Several factors have been studied including 
mechanical stretch, specialized matrix proteins, inflammatory factors, and the TGF-β signaling 
pathway [72, 131, 132].  
A number of studies have characterized regulators of α-SMA transcription. Smad3, a key 
transcription factor in the Smad-dependent TGF-β signaling pathway, induces α-SMA expression 
through its binding with two CAGA motifs, called Smad3-binding elements (SBEs), in the 
promoter of the α-SMA gene [133]. Smad3-independent signaling via p38 and MEK/ERK also 
contributes to α-SMA regulation [134]. Sp1/Sp3 binding to the MCAT enhancer is also 
considered to be necessary for α-SMA expression [135]. In addition to the TGF-β signaling 
pathway, other mechanisms have also been reported to regulate the expression of α-SMA [72]. 
The Notch/CSL pathway regulates α-SMA expression through its promoter activity [136]. 
CCAAT/enhancer binding protein β (C/EBPβ) also induces α-SMA expression in lung fibroblasts 
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[137]. The transcription repressor, Gut-enriched Krüppel-like factor, negatively regulates α-SMA 
by preventing the binding of Smad3 to SBEs [138].  
miR-424 has not previously been reported to be involved in any of the pathways 
mentioned above. Our studies found that miR-424 enhanced the activity of Smad-dependent 
TGF-β signaling, as revealed by a TGF-β signaling reporter assay. This result suggests that the 
up-regulation of α-SMA produced by miR-424 likely occurs through potentiating TGF-β 
signaling. The reporter plasmid we used has a transcription response element (TRE) which can be 
activated by the Smad2/3/4 complexes, and thus the activity of the reporter represents the activity 
of the Smad-dependent TGF-β signaling pathway. The Smads are well-studied intracellular 
effectors of the TGF-β signaling pathway. There are three groups of Smads: receptor-activated 
Smads (R-Smads, Smad2/3), a common Smad (Smad4), and inhibitory Smads (Smad7). Upon 
ligand binding, R-Smads are phosphorylated by phosphorylated type II receptors. The 
phosphorylation of R-Smads on their C-terminal SXS motif results in changes of their 
conformation, causing the exposure of interacting interfaces and two R-Smads, either homomeric 
or heteromeric, and one common Smad form a trimeric complex, which then dissociates from the 
receptors and is translocated into the nucleus, where it acts as a transcription factor regulating 
numerous transcriptional activities [139]. The inhibitory Smad, Smad7, inhibits the TGF-β 
signaling pathway by competitively interfering with R-Smad recruitment and phosphorylation by 
TGF-β receptors [139, 140]. The TGF-β signaling pathway forms an inhibitory feedback loop 
through the induction of Smad7 expression [141].  
Smurf2, another known TGF-β signaling negative regulator, belongs to the family of 
Smad ubiquitin regulatory factors (Smurfs), which are HECT-domain-containing E3 ligases. 
They are748 amino acids long and have several distinctive structural features as compared to 
other E3 ligases, including a phospholipid/calcium-binding C2 domain and WW domains [142]. 
Smurf2 has been reported to directly interact with Smad2 and Smad3 through the linker region 
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containing a PY motif, which is recognized by the WW domain, causing proteasome-dependent 
degradation of Smad2 and Smad3 [143-145]. In addition, Smurf2 can also form a complex with 
Smad7, which then is exported from the nucleus to the cytoplasm and targets the activated TGF-β 
type I receptor to proteasomes for degradation through ubiquitination [145, 146]. 
By using web-based target prediction databases, we found that three inhibitory regulators 
of the TGF-β signaling pathway, Smad7, Smurf1 and Smurf2, were potential targets of miR-424. 
Western blotting showed that the protein level of Smurf2, but not Smurf1 or Smad7, was 
significantly decreased after over-expression of miR-424. Furthermore, the mRNA level of 
Smurf2 was unchanged by miR-424, indicating that the protein change of Smurf2 was not due to 
mRNA cleavage but because of translation, which is the major mechanism of miRNAs in animals. 
Although Smurf1 and Smurf2 share most of the same sequence, Smurf2 acts as a specific 
negative regulator for the Smad signaling pathway [142]. This explains why miR-424 can 
enhance TGF-β signaling by only decreasing the protein level of Smurf2, but not Smurf1. 
miR-424 promoted myofibroblast differentiation, but did not promote EMT in response 
to TGF-β treatment, even though the TGF-β signaling pathway regulates both processes. The 
mechanisms remain to be identified. We speculate that the disparate effects of miR-424 on these 
two processes are due to the specificity of Smad2 and Smad3 in downstream gene expression. 
Knockout of Smad2, but not Smad3, prevents EMT [147], indicating that Smad2 is involved in 
EMT. On the other hand, as mentioned above, Smad3 is believed to be the main regulator of 
TGF-β mediated α-SMA expression [72, 133, 138]. Although Smurf2 has been shown to cause 
the degradation of TβRI, the Smad2 and Smad3 in vitro [143-146] and in vivo study of Smurf2 
knockout mice reveals that Smurf2 does not cause the degradation of Smad2, Smad3 or the TGF-
β type I receptor. However, it does induce the multiple mono-ubiquitination of the Smad3 MH2 
domain to inhibit the formation of Smad3 complexes [142]. This suggests that Smurf2 acts by 
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specifically inhibiting Smad3. Thus, the reduction of Smurf2 by miR-424 enhances the activity of 
Smad3, leading to enhanced α-SMA expression after EMT.  
In summary, we demonstrated a two-step process of EMT: first, human lung epithelial 
cells lose epithelial characteristics and gain mesenchymal markers to become fibroblast-like cells, 
which can be induced by TGF-β treatment alone; and second, the fibroblast-like cells differentiate 
into myofibroblasts, in which miR-424 potentiates TGF-β signaling (Fig. IV.1). 
 
Figure IV.1: miR-424 targets Smurf2 to potentiates TGF-β signaling pathway. Inhibiton of Smurf2 by miR-424 
decreases ubiquitination and degradation of Smad2/3, which further induces transcriptional factors. 
 
 
 
	 	
	
54	
	
4.2 EZH2 and fibroblast differentiation 
Previous studies on EZH2 have mainly been focused on its histone methyltransferase 
activity [96, 100-102, 148-150]. The purpose of this study was to examine the role of EZH2 in the 
development of IPF. We found that EZH2 was up-regulated in the lungs of patients with IPF and 
bleomycin-challenged mice. The inhibition of EZH2 by inhibitor DZNep or EZH2 shRNA 
reduced fibroblast activation in vitro and in vivo. This effect is mediated by EZH2 enhancement 
of TGF-β signaling pathway likely through direct binding of EZH2 with Smad2/3 and thus 
retaining Smad2/3 in the nucleus.  
IPF and cancer share some common characteristics [105, 106, 151]. Several signaling 
pathways such as the Wnt/β-catenin signaling pathway are abnormally activated in both IPF and 
cancer [152] [153]. The global DNA methylation patterns observed in patients with IPF have 
partial similarity to these in cancer [42, 43]. Approximately 10% of the miRNAs are significantly 
changed in IPF and some of them are involved in this disease [76, 86, 88, 90, 92, 104]. Many 
miRNAs also contribute the pathogenesis of cancer [154, 155]. By taking advantage of the 
knowledge from cancer, we may better understand the pathogenesis of IPF [105]. 
Down-regulation of miR-101 in cancer leads to the over-expression of its target EZH2, 
which further results in cancer progression [103, 104]. The over-expression of EZH2 is associated 
with prostate cancer, breast cancer, bladder cancer and lung cancer [100, 101]. Although EZH2 
has extensively been studied in several human cancers, its role in IPF is still unknown. Similar to 
cancer, we found that EZH2 was up-regulated in IPF and its expression level was inversely 
correlated to pulmonary functions in patients with IPF. EZH2 was co-localized with 
myofibroblast marker α-SMA in bleomycin-challenged mice. This result was confirmed by the 
observation that EZH2 expression was higher in primary fibroblasts/myofibroblasts isolated from 
bleomycin-challenged mice that these from control mice. Up-regulation of EZH2 in α-SMA-
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expressing myofibroblasts suggests that EZH2 may be involved in the regulation of 
differentiation of fibroblasts to myofibroblasts.  
Uncontrolled extracellular matrix production in IPF is originated from fibroblastic foci 
[45, 46, 127]. Resident fibroblasts, epithelial cells (via EMT), and fibrocytes contribute to the 
formation of the foci [6]. Three factors are known to induce the differentiation of fibroblasts to 
myofibroblasts: local accumulation of active TGFβ1, high extracellular mechanical stress, and the 
presence of specialized ECM protein [72]. The current study also showed that TGFβ1 treatment 
of human fibroblasts increased the expression of α-SMA and ECM proteins such as Fn and 
COL4A1 as well as collagen gel contractility. EZH2 inhibitor DZNep reduced TGFβ-induced 
expression of these proteins and gel contractility. These data suggest that the inhibition of EZH2 
with DZNep prevent the differentiation of fibroblasts to myofibroblasts.  
DZNep is the cyclopentanyl analog of 3-deazaadanosin and inhibits S-
adenosylhomocysteine (AdoHcy) hydrolase. AdoHcy hydrolase is responsible for the hydrolysis 
of S-adenosylhomocysteine to adenosine and homocysteine. The inhibition of AdoHcy hydrolase 
causes the accumulation of AdoHcy, which in turn results in the inhibition of S-adonosyl-L-
methionine-dependent methyltransferase [117-121]. DZNep has been reported to decrease the 
protein level of EZH2, and has been used as a specific inhibitor of EZH2 [148-150, 156-159]. 
Since DZNep serves as an indirect inhibitor of EZH2, we used gene silencing to confirm the 
inhibitor studies. Similar to the inhibitor studies, the reduction of EZH2 level by EZH2 shRNA 
also reduced α-SMA protein level in TGFβ1-treated fibroblasts.  
TGF-β signaling pathway is involved in α-SMA expression and myofibroblast 
differentiation [160, 161]. Smad3, upon phosphorylation, binds with the Smad3-binding elements 
(SBEs) in the α-SMA promoter to induce α-SMA expression in myofibroblasts [133]. Smad3 is 
also required for ECM secretion in myofibroblasts [162].  
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TGF-β signaling pathway is regulated by many mechanisms [77]. The increase in the 
phosphorylation of Smad2/3 activates TGF-β signaling. However, the inhibition of EZH2 using 
DZNep had no effect on total Smad2/3 or phosphorylated Smad2/3. Thus this is not likely the 
mechanism of EZH2-mediated myofibroblast differentiation.  
The dynamic distribution of Smads between the cytoplasm and nucleus poses a tight 
regulation of the TGFβ signaling pathway. The translocation of phosphorylated Smads from the 
cytoplasm into the nucleus is considered as a rate-limiting step in the TGF-β signal transduction. 
The exporting of Smads out of the nucleus to the cytoplasm turns off the signaling. Nuclear 
import factors moleskin (Msk), importin 7 (Imp7), and Imp8 are responsible for Smad nuclear 
import [163, 164] by interacting with nucleoporins including Sec13, Nup75, Nup93, and Nup205 
[165]. For Smad nuclear export, exportin 4 and RanBP3 have been reported to be involved [166, 
167]. Our result indicates that the inhibition of EZH2 reduced Smad2/3 accumulation in the 
nucleus and in turns reduced the activity of the TGF-β signaling pathway.  
Several mechanisms regulate Smad trafficking between the cytoplasm and nucleus [168]. 
Mono-ubiquitination of Smad4 by the ubiquitin ligase TIF1γ reduced the accumulation of Smad4 
[169]. Phosphorylation in the linker region by cyclin-dependent kinases (CDKs) and MAPK 
inhibits Smad translocation [170, 171]. A kinetic analysis of Smad nucleocytoplasmic trafficking 
shows that nuclear mobility of Smad2 and Smad4 and nuclear export rate of Smad2 are decreased 
in TGFβ1-treated cells, indicating active Smads are trapped in the nucleus [172]. The Smad 
trapping can be explained as a result of retaining of Smads via their interaction with other 
proteins in the nucleus. The transcription factor Yes-associated protein (YAP) and transcriptional 
co-activator with PDZ-binding motif (TAZ) have been shown to directly bind Smads to retain 
Smads in the nucleus [173, 174].  
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EZH2 can interact with several proteins. EZH2 bind EED, SUZ12, and other proteins to 
form PRC2, which catalyzed H3K27me3 and it interacts with transcription factor YY1 [97, 98]. 
A recent study demonstrated that EZH2 was able to bind Smad2 and Smad4 directly [175]. Our 
Co-IP study in pulmonary fibroblasts showed that EZH2 interacts with Smad2 and Smad3. Thus, 
we propose that EZH2 enhances TGFβ signaling pathway by retaining active Smad2/3 in nucleus 
via interaction between EZH2 and Smad2/3. As a result, EZH2 increases α-SMA expression and 
induces myofibroblast differentiation. 
Several animal models of experimental lung fibrosis have been developed for studying 
the pathogenesis of IPF,  including exposure to bleomycin, silica, fluorescein isothiocyanate,  
irradiation, or expression of specific genes using a transgenic system [176]. Bleomycin is an anti-
cancer chemotherapeutic drug that causes pulmonary fibrosis as a major adverse drug effect. It 
breaks DNA strand directly as well as induces oxidative stress to cause fibrosis [177]. Although 
bleomycin model has some limitations [176, 177], a single dose of intratracheal delivery of 
bleomycin remains the mostly frequently used method, mainly due to its easily delivery, short 
time in inducing fibrosis, and some histological hallmarks similar to IPF.  
 Using intratracheally delivery of a single dose of bleomycin model [178], we found that 
EZH2 was significantly up-regulated. This model provides us a tool to evaluate the effect of 
EZH2 inhibitor DZNep on pulmonary fibrosis in vivo. DZNep does not have any obvious toxicity 
when administrated at a dose of 10 mg/kg single dose [179]. The effects of DZNep in various 
cancer models have been reported. Intravenous administration of DZNep inhibits angiogenesis in 
a subcutaneous glioblastoma mouse model without toxicities [180]. Intraperitoneal delivery of 
DZNep and histone deacetylase inhibitor panobinostat increases animal survival in an acute 
myeloid leukemia mouse model [150]. In the leukemia-engrafted mouse model of AML, 
intraperitoneal administration of DZNep reduces tumor growth and prolongs the survival of 
animals [181]. DZNep-treated prostate cancer cells showed reduced tumorigenicity in vivo [182]. 
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In this study, we found that intraperitoneal administration of DZNep reduced pulmonary fibrosis 
in bleomycin-induced pulmonary fibrosis mouse model. 
In summary, we discovered that EZH2 is up-regulation of EZH2 in IPF and it promotes 
the differentiation of pulmonary fibroblasts to myofibroblasts. We also revealed a new 
mechanism of EZH2 action, i.e. enhancing TGFβ signaling pathway retaining Smad2/3 in the 
nucleus via a direct interaction between EZH2 and Smad2/3 (Fig. IV.2). In vivo studies showed 
inhibition of EZH2 by DZNep reduced pulmonary fibrosis.   
 
Figure IV.2: EZH2 retains phosphor-Smad2/3 in the nucleus. Up-regulated EZH2 binds to phosphor-Smad2/3 to 
induce the accumulation of phosphor-Smad2/3.  
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CHAPTER V 
 
 
SUMMARY AND CONCLUSION 
 
Idiopathic pulmonary fibrosis (IPF) is one of the most common and severe interstitial 
lung diseases. The etiology is still unknown. Understanding the pathogenesis of IPF will provide 
therapeutic targets for treating this disease. 
EMT has been shown to participate in the process of IPF. A number of miRNAs have 
been reported to be involved in fibrotic diseases. However, no direct evidence has been presented 
to show that miRNAs regulate EMT in human lung epithelial cells. We identified 6 up-regulated 
and 3 down-regulated miRNAs in a human lung epithelial cell EMT model using miRNA 
microarray and real-time PCR. Overexpression of one of these up-regulated miRNAs, miR-424, 
increased the expression of α-smooth muscle actin, an indicator of myofibroblast differentiation, 
but had no effects on the epithelial or mesenchymal cell markers. miR-424 enhanced the activity 
of the TGF-β signaling pathway, as demonstrated by a luciferase reporter assay. Further 
experiments showed that miR-424 decreased the protein expression of Smurf2, a negative 
regulator of TGF-β signaling, indicating that miR-424 exerts a forward regulatory loop in the 
TGF-β signaling pathway. Our results suggest that miR-424 regulates the myofibroblast 
differentiation during EMT by potentiating the TGF-β signaling pathway, likely through Smurf2. 
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Fibroblastic foci represent a hallmark of the histopathology of IPF. They are composed of 
fibroblasts/myofibroblasts. Abnormally activated/differentiated myofibroblasts exaggerate the 
ECM accumulation.  We investigated the role of EZH2 in the differentiation of  fibroblasts into 
myofibroblasts and underlying mechanisms. We found that EZH2 was up-regulated in the lungs 
of patients with IPF and mice with bleomycin-induced lung fibrosis. The up-regulation of EZH2 
occurred in myofibroblasts. The inhibition of EZH2 by its inhibitor DZNep or shRNA reduced 
TGFβ1-induced differentiation of human lung fibroblasts into myofibroblasts as demonstrated by 
the expression of myofibroblast marker α-smooth muscle actin, fibronectin and COLA4A1 as 
well as contractility. DZNep inhibited Smad2/3 nuclear translocation without affecting Smad2/3 
phosphorylation. Co-immunoprecipitation revealed a direct interaction between EZH2 and 
Smad2/3. DZNep treatment attenuated bleomycin-induced pulmonary fibrosis in mice. We 
conclude that EZH2 induces the differentiation of fibroblasts to myofibroblasts by binding and 
retaining Smad2/3 in the nucleus. 
  In summary, we demonstrated a two-step process of EMT: first, human lung epithelial 
cells lose epithelial characteristics and gain mesenchymal markers to become fibroblast-like cells, 
which can be induced by TGF-β treatment alone; and second, the fibroblast-like cells differentiate 
into myofibroblasts, in which miR-424 potentiates TGF-β signaling. We also discovered that 
EZH2 is up-regulation of EZH2 in IPF and it promotes the differentiation of pulmonary 
fibroblasts to myofibroblasts. We also revealed a new mechanism of EZH2 action, i.e. enhancing 
TGFβ signaling pathway retaining Smad2/3 in the nucleus via a direct interaction between EZH2 
and Smad2/3. In vivo studies showed inhibition of EZH2 by DZNep reduced pulmonary fibrosis.  
Our study on the roles of miR-424 in EMT and of EZH2 in fibroblast differentiation could lead to 
further development of antifibrotic drugs. 
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